MCID: PRD017
MIFTS: 22

Periodic Paralyses malady

Genetic diseases (common) category

Aliases & Classifications for Periodic Paralyses

About this section

Aliases & Descriptions for Periodic Paralyses:

Name: Periodic Paralyses 46


Classifications:



Summaries for Periodic Paralyses

About this section
NINDS:46 Familial periodic paralyses are a group of inherited neurological disorders caused by mutations in genes that regulate sodium and calcium channels in nerve cells. They are characterized by episodes in which the affected muscles become slack, weak, and unable to contract. Between attacks, the affected muscles usually work as normal.

MalaCards based summary: Periodic Paralyses is related to paramyotonia congenita and hypokalemic periodic paralysis, type 1. An important gene associated with Periodic Paralyses is KCNJ2 (Potassium Channel, Inwardly Rectifying Subfamily J, Member 2), and among its related pathways are Antiarrhythmic Pathway, Pharmacodynamics and Oxytocin signaling pathway. Affiliated tissues include skeletal muscle, and related mouse phenotypes are digestive/alimentary and muscle.

Related Diseases for Periodic Paralyses

About this section

Graphical network of the top 20 diseases related to Periodic Paralyses:



Diseases related to periodic paralyses

Symptoms for Periodic Paralyses

About this section

Drugs & Therapeutics for Periodic Paralyses

About this section

Drugs for Periodic Paralyses (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DichlorphenamideapprovedPhase 32120-97-83038
Synonyms:
1,3-Disulfamoyl-4,5-dichlorobenzene
1,3-Disulfamyl-4,5-dichlorobenzene
1,3-disulfamoyl-4,5-dichlorobenzene
120-97-8
2pou
3,4-Dichloro-5-sulfamylbenzenesulfonamide
4,5-DICHLOROBENZENE-1,3-disulfonamide
4,5-Dichloro-1,3-benzenedisulfonamide
4,5-Dichloro-1,3-disulfamoylbenzene
4,5-Dichloro-benzene-1,3-disulfonic acid diamide
4,5-Dichloro-m-benzenedisulfonamide
4,5-Dicholorobenzene-1,3-disulfonamide
4,5-dichloro-1,3-disulfamoylbenzene
4,5-dichloro-m-benzenedisulfonamide
4,5-dichlorobenzene-1,3-disulfonamide
AC1L1F18
Antidrasi
BPBio1_000745
BRD-K71499074-001-03-8
BRN 2703329
BSPBio_000677
Barastonin
C07459
C6H6Cl2N2O4S2
CAS-120-97-8
CB 8000
CHEBI:101085
CHEMBL17
CID3038
D004005
D00518
DB01144
DB07948
Daranide
Daranide (TN)
Dasanide
Dichlofenamide
Dichlorophenamide
Dichlorophenamide (DCP)
 
Dichlorphenamid
Dichlorphenamide
Dichlorphenamide (USP)
Dichlorphenamide [BAN]
Diclofenamid
Diclofenamida
Diclofenamida [INN-Spanish]
Diclofenamide
Diclofenamide (JP15/INN)
Diclofenamidum
Diclofenamidum [INN-Latin]
EINECS 204-440-6
FT-0084528
Glafco
Glajust
Glaucol
Glauconide
Glaumid
HMS1570B19
HSDB 3267
I7A
LS-30043
Llorens Brand of Dichlorphenamide
MLS002154010
Merck Brand of Dichlorphenamide
MolPort-004-285-635
NCGC00016371-01
NCGC00016371-02
Oratrol
Prestwick0_000809
Prestwick1_000809
Prestwick2_000809
Prestwick3_000809
Prestwick_1071
S2177_Selleck
SBB058142
SMR001233338
SPBio_002598
UNII-VVJ6673MHY
ZINC00896918
dichlorphenamide
2
Lamotrigineapproved, investigationalPhase 317484057-84-13878
Synonyms:
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine
6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
84057-84-1
AC-10298
AC1L1GWT
BIDD:GT0794
BW 430C
BW-430C
Bio-0056
C047781
CHEBI:138727
CHEBI:6367
CHEMBL741
CID3878
CPD000058464
Crisomet
D00354
DB00555
Desitin Brand of Lamotrigine
EINECS 281-901-8
EU-0100688
EUR-1048
Faes Brand of Lamotrigine
GI 267119X
GW 273293
Glaxo Wellcome Brand of Lamotrigine
GlaxoSmithKline Brand of Lamotrigine
HMS2051C10
HMS2089M08
HMS2093P21
HSDB 7526
Juste Brand of Lamotrigine
L 3791
L3791_SIGMA
LS-155249
 
Labileno
Lamictal
Lamictal (TN)
Lamictal CD
Lamictal Cd
Lamictal ODT
Lamictal XR
Lamictin
Lamiktal
Lamitor
Lamotrigina
Lamotrigina [Spanish]
Lamotrigine
Lamotrigine (JAN/USAN/INN)
Lamotrigine [USAN:INN:BAN]
Lamotriginum
Lamotriginum [Latin]
Lopac-L-3791
Lopac0_000688
MLS000069685
MLS000759486
MLS001077325
MolPort-003-666-744
NCGC00015605-01
NCGC00015605-02
NCGC00015605-06
NCGC00015605-08
NCGC00022936-02
NCGC00022936-04
NCGC00022936-05
NSC746307
SAM001246697
SMP2_000303
SMR000058464
STK628377
Tocris-1611
UNII-U3H27498KS
ZINC00013156
lamotrigine
3Calcium, DietaryPhase 33529
4HopsNutraceuticalPhase 330
5
BumetanideapprovedPhase 21328395-03-12471
Synonyms:
28395-03-1
3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid
3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid
3-Butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
3-Butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
3-Butylamino-4-phenoxy-5-sulfamoylbenzoic acid
3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
AB00052253
AC-15228
AC1L1DR5
Aquazone
AstraZeneca Brand of Bumetanide
Atlantis Brand of Bumetanide
B 3023
B3023_SIGMA
BPBio1_000168
BRD-K38197229-001-06-7
BRN 2185351
BSPBio_000152
BSPBio_001508
BSPBio_003061
Bio1_000421
Bio1_000910
Bio1_001399
Bio2_000228
Bio2_000708
Bumedyl
Bumetanida
Bumetanida [INN-Spanish]
Bumetanide
Bumetanide (JP15/USP)
Bumetanide (JP15/USP/INN)
Bumetanide AstraZeneca Brand
Bumetanide Atlantis Brand
Bumetanide Farmacusi Brand
Bumetanide Grossmann Brand
Bumetanide Leo Brand
Bumetanide Roche Brand
Bumetanide Senosiain Brand
Bumetanide [USAN:BAN:INN:JAN]
Bumetanidum
Bumetanidum [INN-Latin]
Bumethanide
Bumex
Bumex (TN)
Bumex, Bumetanide
Burine
Burinex
Butinat
C17H20N2O5S
CAS-28395-03-1
CHEBI:3213
CHEMBL1072
CID2471
CPD000058418
Cambiex
D002034
D00247
DB00887
Diurama
DivK1c_000034
Drenural
EINECS 249-004-6
EU-0100162
Farmacusi Brand of Bumetanide
Fontego
Fordiuran
Grossmann Brand of Bumetanide
HMS1361L10
HMS1568H14
HMS1791L10
 
HMS1921B20
HMS1989L10
HMS2089P13
HMS2092N03
HMS500B16
I06-2277
IDI1_000034
IDI1_033978
KBio1_000034
KBio2_000228
KBio2_001797
KBio2_002796
KBio2_004365
KBio2_005364
KBio2_006933
KBio3_000455
KBio3_000456
KBio3_002561
KBioGR_000228
KBioGR_000439
KBioSS_000228
KBioSS_001797
LS-36330
Leo Brand of Bumetanide
Lixil
Lixil-Leo
Lopac-B-3023
Lopac0_000162
Lunetoron
MLS000028457
MLS001148265
Miccil
MolPort-003-666-390
NCGC00015149-01
NCGC00015149-02
NCGC00015149-03
NCGC00015149-06
NCGC00015149-12
NCGC00022072-03
NCGC00022072-04
NCGC00022072-05
NCGC00022072-06
NCGC00022072-07
NCGC00022072-08
NINDS_000034
PF 1593
PF-1593
PF1593
Prestwick0_000276
Prestwick1_000276
Prestwick2_000276
Prestwick3_000276
Prestwick_679
Ro 10-6338
Ro-10-6338
Roche Brand of Bumetanide
S1287_Selleck
SAM002564195
SMP1_000049
SMR000058418
SPBio_000980
SPBio_002371
SPECTRUM1502004
ST51014910
Segurex
Senosiain Brand of Bumetanide
Spectrum2_001050
Spectrum3_001481
Spectrum4_000030
Spectrum5_001212
Spectrum_001317
UNII-0Y2S3XUQ5H
Yurinex
bumetanide

Interventional clinical trials:

idNameStatusNCT IDPhase
1Hyper- and Hypokalemic Periodic Paralysis StudyCompletedNCT00494507Phase 3
2Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel DisordersCompletedNCT00004802Phase 3
3Lamotrigine as Treatment of MyotoniaEnrolling by invitationNCT01939561Phase 3
4Bumetanide in Hypokalaemic Periodic ParalysisRecruitingNCT02582476Phase 2
5Use of Minocicline in Patients With StrokeRecruitingNCT01556802Phase 1
6Genetic Analysis of Thyrotoxic Periodic ParalysisCompletedNCT00443833
7Characteristics of Andersen-Tawil SyndromeCompletedNCT00521794
8Genetic and Morphological Analysis of Thyrotoxic Periodic ParalysisActive, not recruitingNCT02287363

Search NIH Clinical Center for Periodic Paralyses

Genetic Tests for Periodic Paralyses

About this section

Anatomical Context for Periodic Paralyses

About this section

MalaCards organs/tissues related to Periodic Paralyses:

33
Skeletal muscle

Animal Models for Periodic Paralyses or affiliated genes

About this section

MGI Mouse Phenotypes related to Periodic Paralyses:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.7CACNA1S, KCNE3, KCNJ2
2MP:00053698.5CACNA1S, KCNJ2, SCN4A

Publications for Periodic Paralyses

About this section

Articles related to Periodic Paralyses:

(show all 32)
idTitleAuthorsYear
1
Molecular cloning of ion channels in Felis catus that are related to periodic paralyses in man: a contribution to the understanding of the genetic susceptibility to feline neck ventroflexion and paralysis. (25063199)
2014
2
Muscle channelopathies: the nondystrophic myotonias and periodic paralyses. (24305449)
2013
3
Pathophysiologic and anesthetic considerations for patients with myotonia congenita or periodic paralyses. (23802937)
2013
4
Recent advances in the pathogenesis and drug action in periodic paralyses and related channelopathies. (21687503)
2011
5
Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias. (19571750)
2009
6
Periodic paralyses: when channels go wrong. (18281721)
2008
7
Primary periodic paralyses. (18031562)
2008
8
The primary periodic paralyses: diagnosis, pathogenesis and treatment. (16195244)
2006
9
Paroxysmal muscle weakness: the familial periodic paralyses. (17139526)
2006
10
Correlating phenotype and genotype in the periodic paralyses. (15534250)
2004
11
Patient page. Attacks of immobility caused by diet or exercise? The mystery of periodic paralyses. (15534231)
2004
12
Periodic paralyses and nondystrophic myotonias. (11908229)
2002
13
Sleep complaints in periodic paralyses: a web survey. (11769870)
2001
14
Channelopathies: potassium-related periodic paralyses and similar disorders. (11235435)
2000
15
Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses. (10720928)
2000
16
Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. (10632100)
2000
17
Periodic paralyses. (10658175)
2000
18
The familial periodic paralyses and nondystrophic myotonias. (9688022)
1998
19
Muscle fiber conduction velocity in situ in hypokalemic periodic paralyses. (9325474)
1997
20
Paramyotonia, potassium-aggravated myotonias and periodic paralyses. 37th ENMC International Workshop, Naarden, The Netherlands, 8-10 December 1995. (9131654)
1997
21
Channelopathies: the nondystrophic myotonias and periodic paralyses. (8795846)
1996
22
Periodic paralyses. (8771893)
1996
23
Non-dystrophic myotonias and periodic paralyses. A European Neuromuscular Center Workshop held 4-6 October 1992, Ulm, Germany. (7689382)
1993
24
The periodic paralyses. (1331137)
1992
25
Sodium channel gene defects in the periodic paralyses. (1330128)
1992
26
Are myotonias and periodic paralyses associated with susceptibility to malignant hyperthermia? (2248848)
1990
27
The periodic paralyses. (3065596)
1988
28
The myotonic disorders and the periodic paralyses. (888733)
1977
29
A summary review of the diagnosis and pathology of the primary familial periodic paralyses. (1094905)
1975
30
Calcification within muscle fibres in the periodic paralyses. (4255134)
1971
31
Electron microscopic observations in primary hypokalemic and thyrotoxic periodic paralyses. (5957594)
1966
32
THE PERIODIC PARALYSES: DIFFERENTIAL FEATURES AND PATHOLOGICAL OBSERVATIONS IN PERMANENT MYOPATHIC WEAKNESS. (14188278)
1964

Variations for Periodic Paralyses

About this section

Expression for genes affiliated with Periodic Paralyses

About this section
Search GEO for disease gene expression data for Periodic Paralyses.

Pathways for genes affiliated with Periodic Paralyses

About this section

Pathways related to Periodic Paralyses according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.4KCNE3, KCNJ2
2
Show member pathways
9.1CACNA1S, KCNJ2
39.1CACNA1S, KCNJ2
48.6CACNA1S, KCNE3, KCNJ2

GO Terms for genes affiliated with Periodic Paralyses

About this section

Cellular components related to Periodic Paralyses according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1voltage-gated potassium channel complexGO:00080769.4KCNE3, KCNJ2
2T-tubuleGO:00303159.0CACNA1S, KCNJ2

Biological processes related to Periodic Paralyses according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1potassium ion transmembrane transportGO:00718059.9KCNE3, KCNJ2
2regulation of membrane repolarizationGO:00603069.8KCNE3, KCNJ2
3membrane depolarization during action potentialGO:00860109.3CACNA1S, SCN4A
4regulation of ion transmembrane transportGO:00347659.1CACNA1S, SCN4A
5muscle contractionGO:00069369.0CACNA1S, SCN4A
6ion transportGO:00068118.2CACNA1S, KCNE3, SCN4A

Molecular functions related to Periodic Paralyses according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ion channel activityGO:00052169.0CACNA1S, SCN4A

Sources for Periodic Paralyses

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet